CURE: Prior Stroke or TIA

Outcome C + ASA ASA HR P value

MI/stroke/CV death

49/274 (17.9%) 52/232 (22.4) 0.74 (0.50, 1.10) 0.13

Non-CABG TIMI major bleeding

2/274 (0.7%) 2/232 (0.9%) 0.83 (0.12, 5.88) 0.85

Net clinicalbenefit outcome

49/274 (17.9%) 60/232 (25.9%) 0.64 (0.44, 0.93) 0.02

(N=506)

No significant interaction for any outcome

Courtesy of Dr. John Eikelboom

C=clopidogrelC=clopidogrel

CURE trial (unpublished data)

CURE: Prior Stroke, Age ≥75, Weight <60 kg

Outcome C + ASA ASA HR (95% CI) P value

MI/stroke/CV death

279/1763 (15.8%) 303/1732 (17.5%) 0.89 (0.75, 1.04) 0.15

Non-CABG TIMI major bleeding

19/1763 (1.1%) 15/1732 (0.9%) 1.23 (0.63, 2.42) 0.55

Net clinical benefit outcome

298/1763 (16.9%) 334/1732 (19.3%) 0.86 (0.73, 1.00) 0.05

(N=3495)

No significant interaction for any outcome CURE trial (unpublished data)

Courtesy of Dr. John Eikelboom

CURE and TRITON-TIMI 38: Prior Stroke or TIA

OutcomeRelative risk Absolute risk

CURE TRITON CURE TRITON

MI/stroke/CV death ↓26% ↑37% ↓45/1000 ↑47/1000

Non-CABG TIMI major bleeding

↓17% ↑146% ↓2/1000 ↑21/1000

Net clinical benefit outcome

↓36%* ↑54%* ↓80/1000* ↑70/1000*

*P<0.05

Courtesy of Dr. John Eikelboom; Wiviott et al. N Engl J Med 2007;357(20):2001-15.

CURE trial (unpublished data)